On 25 November 2020, the European Commission launched the Pharmaceutical Strategy for Europe to ensure that patients have access to innovative and affordable medicines and to support the competitiveness, innovative capacity, and sustainability of the European Union’s pharmaceutical industry. The Strategy will support patient-centred innovations and accommodate digital and technological change.

The Women’s Brain Project (WBP) is delighted to see that the European Commission recognises that treatments for neurodegenerative diseases are still lacking and we need to stimulate innovation in this area. Moreover, it’s great to see that gender has been highlighted as a critical factor to consider in terms of clinical trials, artificial intelligence and unmet needs.

As an international non-profit organisation studying sex and gender determinants of brain and mental health to achieve precision medicine, we applaud the European Commission for highlighting the following key issues:

Flagship initiatives have also been put forward in the Pharmaceutical Strategy for Europe to address these very important issues.

WBP will closely follow the developments on the Pharmaceutical Strategy for Europe and looks forward to working with the EU institutions to ensure that we reach the best possible outcome for both science and patients.

Leave a Reply

Your email address will not be published. Required fields are marked *